Impact of Maternal BMI on Plasma Levels of Oxytocin During Labor Augmentation

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04093479

Enrollment

Registered

2019-09-18

Start date

2019-10-01

Completion date

2020-08-01

Last updated

2021-02-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Labor; Arrested Active Phase, Maternal Obesity During Childbirth

Keywords

labor, obesity, oxytocin

Brief summary

The aim of this study is to examine the associations between maternal BMI and levels of oxytocin in maternal plasma during augmentation with oxytocin during first stage of labor in term pregnancy.

Detailed description

A translational prospective experimental study in the delivery ward in Linköping. The study population will include women in two BMI groups (underweight/normal weight and overweight/obese) during first stage of labor with singleton full term pregnancy and cephalic presentation.The BMI is calculated from weight and height registered at the first antenatal visit around week 8-12. At the delivery ward, if the women are in need of labor augmentation with oxytocin infusion, a peripheral venous catheter will be placed in the contralateral arm from the arm where oxytocin will be administrated. The oxytocin infusion will be prepared to a concentration of 10 mU/ml and will be given according to a standardized protocol or to an infusion level giving maximum of 5 uterine contractions per 10 minutes. Blood samples for measuring plasma levels of oxytocin will be taken prior to start and before every increase in the rate of oxytocin infusion. The blood samples will be collected through the first stage of labor.

Interventions

OTHERblood samples

blood samples will be taken repeatedly

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to No maximum

Inclusion criteria

Full-term pregnancy (from gestational week 37+0), singel pregnancy, vertex presentation, knowledge in the Swedish language, 18 years and older, known BMI, need of labor augmentation with oxytocin infusion during opening stage.

Exclusion criteria

Not participating in other studies at the delivery ward

Design outcomes

Primary

Measure	Time frame	Description
maternal BMI, were weight and height will be combined to report BMI in kg/m^2	eight hours	mass spectrometry
level of oxytocin in plasma during oxytocin infusion	eight hours	mass spectrometry

Countries

Sweden

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 8, 2026